keyword
MENU ▼
Read by QxMD icon Read
search

Neuroendocrine carcinoma

keyword
https://www.readbyqxmd.com/read/28228868/primary-neuroendocrine-carcinoma-of-the-breast-report-of-2-cases-and-literature-review
#1
Fernando Collado-Mesa, Jose M Net, Geetika A Klevos, Monica M Yepes
Neuroendocrine tumors of the breast are very rare accounting for less than 0.1% of all breast cancers and less than 1% of all neuroendocrine tumors. Focal neuroendocrine differentiation can be found in different histologic types of breast carcinoma including in situ and invasive ductal or invasive lobular. However, primary neuroendocrine carcinoma of the breast requires the expression of neuroendocrine markers in more than 50% of the cell population, the presence of ductal carcinoma in situ, and the absence of clinical evidence of concurrent primary neuroendocrine carcinoma of any other organ...
March 2017: Radiology case reports
https://www.readbyqxmd.com/read/28228710/her2-positive-neuroendocrine-breast-cancer-case-report-and-review-of-literature
#2
Arpine Gevorgyan, Giacomo Bregni, Giulia Galli, Elisa Zanardi, Filippo de Braud, Serena Di Cosimo
BACKGROUND: Neuroendocrine carcinoma is an uncommon histology for breast cancer. CASE REPORT: Our patient underwent right quadrantectomy for a neuroendocrine carcinoma in 1984 and had a bone relapse 30 years later. After thorough pathological and immunohistochemical analysis the diagnosis was confirmed and HER2 amplification was observed. Here we discuss the management, rationale and results of HER2-targeted therapy in advanced neuroendocrine breast carcinoma.
December 2016: Breast Care
https://www.readbyqxmd.com/read/28214210/pathologic-features-of-colorectal-carcinomas-associated-with-crohn-s-disease-in-korean-population
#3
Jiyoon Kim, Ho-Su Lee, Sang Hyoung Park, Suk-Kyun Yang, Byong Duk Ye, Dong-Hoon Yang, Kyung-Jo Kim, Jeong-Sik Byeon, Yong Sik Yoon, Chang Sik Yu, Jihun Kim
BACKGROUND: Colorectal cancer (CRC) has been known to complicate Crohn's disease (CD). Several reports in Western population revealed that CRC in CD were characterized by much younger onset and equal distribution of tumors along the entire colon. However, clinicopathologic features of CD-associated CRC in Korean population have not been well documented yet. METHODS: Among 2968 Korean CD patients, 16 patients (0.54%) were found to develop CRC during follow up. We reviewed clinicopathologic features of the 16 CRC patients...
December 21, 2016: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28210088/clinicopathological-treatment-and-prognosis-study-of-43-gastric-neuroendocrine-carcinomas
#4
De-Jun Liu, Xue-Liang Fu, Wei Liu, Lu-Ying Zheng, Jun-Feng Zhang, Yan-Miao Huo, Jiao Li, Rong Hua, Qiang Liu, Yong-Wei Sun
AIM: To provide more information and therapeutic methods about gastric neuroendocrine carcinomas (G-NECs) which occur rarely but are highly malignant and clinically challenging. METHODS: We retrospectively analyzed the clinicopathological characteristics, treatments, and prognosis of 43 G-NEC patients at our hospital between January 2007 and December 2014. The diagnosis was based on the 2010 World Health Organization criteria. RESULTS: Forty-three G-NECs containing 39 small cell carcinomas and 4 large cell NECs with Ki67 > 60% were included in this study, accounting for only 0...
January 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28208131/pulmonary-carcinoids-and-low-grade-gastrointestinal-neuroendocrine-tumors-show-common-microrna-expression-profiles-different-from-adenocarcinomas-and-small-cell-carcinomas
#5
Toyoki Yoshimoto, Noriko Motoi, Noriko Yamamoto, Hiroko Nagano, Masaru Ushijima, Masaaki Matsuura, Sakae Okumura, Toshiharu Yamaguchi, Masashi Fukayama, Yuichi Ishikawa
No abstract text is available yet for this article.
February 17, 2017: Neuroendocrinology
https://www.readbyqxmd.com/read/28206942/mixed-hepatocellular-carcinoma-neuroendocrine-carcinoma-of-the-liver
#6
Erin Baker, Carl Jacobs, John Martinie, David A Iannitti, Dionisios Vrochides, Ryan Z Swan
We present the case of a 76-year-old male found to have a large tumor involving the left lateral lobe of the liver, presumed to be hepatocellular carcinoma (HCC). After resection, pathologic features demonstrated both high-grade HCC and high-grade neuroendocrine carcinoma (NEC). Areas of NEC stained strongly for synaptophysin, which was not present in HCC component. The HCC component stained strongly for Hep-Par 1, which was not present in the NEC component. The patient underwent genetic analysis for biomarkers common to both tumor cell types...
November 1, 2016: American Surgeon
https://www.readbyqxmd.com/read/28204910/outcomes-of-curative-intent-surgery-and-adjuvant-treatment-for-pulmonary-large-cell-neuroendocrine-carcinoma
#7
Kun Woo Kim, Hong Kwan Kim, Jhingook Kim, Young Mog Shim, Myung-Ju Ahn, Yoon-La Choi
BACKGROUND: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is pathologically classified as non-small-cell lung cancer (NSCLC), but its clinical behavior is more aggressive than other types of NSCLC. Accordingly, the optimal treatment strategy for LCNEC, including the indication of adjuvant treatment, remains controversial. METHODS: A retrospective review of 139 patients who underwent curative-intent surgery for LCNEC was performed to investigate clinicopathologic features and survival outcomes and to evaluate whether adjuvant treatment affected survival outcomes...
February 15, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28203418/clinical-outcomes-of-surgically-resected-combined-small-cell-lung-cancer-a-two-institutional-experience
#8
Chao Zhang, Haitang Yang, Heng Zhao, Baoping Lang, Xiangdong Yu, Peng Xiao, Xiao Zhang
BACKGROUND: The combined small cell lung cancer (c-SCLC) was rare and its clinicopathological characteristics had not been thoroughly described. The aim of this study was to determine prognostic factors and survival in c-SCLC patients. METHODS: Clinical records of patients with c-SCLC who underwent surgery between January 2009 and December 2013 in two institutions were retrospectively reviewed. RESULTS: Ninety-seven patients were identified...
January 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28199067/human-epididymis-protein-4-immunostaining-of-malignant-ascites-differentiates-cancer-of-m%C3%A3-llerian-origin-from-gastrointestinal-cancer
#9
Anna Stiekema, Koen K Van de Vijver, Henk Boot, Annegien Broeks, Catharina M Korse, Willemien J van Driel, Gemma G Kenter, Christianne A R Lok
BACKGROUND: An accurate diagnosis of cancer of Müllerian origin is required before the initiation of treatment. An overlap in clinical presentation and cytological, histological, or imaging studies with other nongynecological tumors does occur. Therefore, immunocytochemistry markers are used to determine tumor origin. Human epididymis protein 4 (HE4) is overexpressed in tissue of epithelial ovarian cancer (EOC). It has shown to be a sensitive and specific serum marker for EOC and to be of value for the differentiation between EOC and ovarian metastases of gastrointestinal origin...
February 15, 2017: Cancer
https://www.readbyqxmd.com/read/28197925/giant-prolactinoma-presenting-as-a-base-of-skull-tumor-with-nasopharyngeal-extension-a-potential-diagnostic-pitfall-in-neuroendocrine-lesions-of-the-base-of-skull
#10
Amy Prawira, Dorothy Lazinski, Lillian L Siu, Bayardo Perez-Ordonez
Pituitary adenomas presenting in uncommon anatomical locations are commonly misdiagnosed. Dramatic clinical presentation with hemorrhage and infarction, along with a lack of endocrine symptoms may further confound the diagnosis in some patients as illustrated in one of our two previously reported cases of non-small cell neuroendocrine carcinoma of the sinonasal tract and nasopharynx. This report presents the clinical progress of case number 2, which has a revised diagnosis of giant lactotroph pituitary adenoma...
February 14, 2017: Head and Neck Pathology
https://www.readbyqxmd.com/read/28197686/pre-therapeutic-factors-for-predicting-survival-after-radioembolization-a-single-center-experience-in-389-patients
#11
K J Paprottka, F Schoeppe, M Ingrisch, J Rübenthaler, N N Sommer, E De Toni, H Ilhan, M Zacherl, A Todica, P M Paprottka
PURPOSE: To determine pre-therapeutic predictive factors for overall survival (OS) after yttrium (Y)-90 radioembolization (RE). METHODS: We retrospectively analyzed the pre-therapeutic characteristics (sex, age, tumor entity, hepatic tumor burden, extrahepatic disease [EHD] and liver function [with focus on bilirubin and cholinesterase level]) of 389 consecutive patients with various refractory liver-dominant tumors (hepatocellular carcinoma [HCC], cholangiocarcinoma [CCC], neuroendocrine tumor [NET], colorectal cancer [CRC] and metastatic breast cancer [MBC]), who received Y-90 radioembolization for predicting survival...
February 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28195647/molecular-classification-of-urothelial-carcinoma-global-mrna-classification-versus-tumour-cell-phenotype-classification
#12
Gottfrid Sjödahl, Pontus Eriksson, Fredrik Liedberg, Mattias Höglund
Global mRNA expression analysis is efficient for phenotypic profiling of tumours and has been used to define molecular subtypes for almost every major tumour type. A key limitation is that most tumours are communities of both tumour and non-tumour cells. This problem is particularly pertinent when analysing advanced invasive tumours, known to induce major changes and responses in both the tumour and the surrounding tissue. To identify bladder cancer tumour-cell phenotypes and compare classification by tumour-cell phenotype with classification by global gene expression analysis, we analysed 307 advanced bladder cancers (cystectomised) both by genome gene expression analysis and by immunohistochemistry using antibodies for 28 proteins...
February 13, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28195104/well-differentiated-neuroendocrine-tumor-of-the-kidney-report-of-a-rare-case-with-review-of-literature
#13
Kavita Mardi, Lalita Negi, Srijan Srivastava
Neuroendocrine tumors (NETs) are uncommon tumors that exhibit a wide range of neuroendocrine differentiation and biological behavior. Primary NETs of the kidney, including carcinoid tumor, small cell carcinoma (SCC), and large cell neuroendocrine carcinoma (LCNEC) are exceedingly rare. Renal carcinoids are typically slow-growing tumors and pursue a variable clinical course. In contrast, SCC and LCNEC often present with locally advanced or metastatic disease and carry a poor prognosis. We herein report a rare cases of well-differentiated NET (carcinoid) in a 39-year-old male along with the immunohistochemical features...
January 2017: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/28191812/moderately-differentiated-neuroendocrine-cell-carcinoma-of-the-vulva-a-case-report-and-review-of-the-literature
#14
Soheila Aminimoghaddam, A Maghsoudnia, S Shafiee
Primary vulvar neuroendocrine carcinoma are extremely rare. There have been few cases of these tumors most of which have been considered as Merkel cell carcinoma. This report describes a moderately differentiated neuroendocrine cell carcinoma that was not compatible to any of previously reported cases. The patient underwent left hemivulvectomy and bilateral inguinal lymph node dissection. Pathology examination revealed a 5×5 cm mass with no lymph node involvement. Post-op evaluation ruled out any regional and distant metastasis and thereby did not receive chemotherapy or radiotherapy...
September 2016: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/28188377/-neuroendocrine-neoplasia-of-the-stomach-what-is-new
#15
T Knösel, C Reiter, G Schubert-Fritschle, A Altendorf-Hofmann, T Kirchner
INTRODUCTION: Neuroendocrine Neoplasms are classified according to the new WHO classification in (1.) well differentiated neuroendocrine tumors G1 (NET G1, Ki67 ≤ 2 or mitosis count <2) and (2.) well differentiated neuroendocrine tumors G2 (NET G2, Ki67 3-20 or mitosis count 2-20) and (3.) poorly differentiated neuroendocrine carcinomas G3 (NEC G3, Ki67 > 20 or mitosis count >20). MATERIAL AND METHODS: In this study 310 NENs of the Ludwig-Maximilians-University in Munich were reevaluated according to the new WHO classification...
February 10, 2017: Der Pathologe
https://www.readbyqxmd.com/read/28182792/somatostatin-receptor-staining-in-ffpe-sections-using-a-ligand-derivative-dye-as-an-alternative-to-immunostaining
#16
Koki Hasegawa, Shinji Kudoh, Takaaki Ito
The confirmation of target expression in tissues is a prerequisite for molecular-targeted therapy. However, difficulties are sometimes associated with the production of appropriate antibodies against receptors. We herein developed a ligand derivative dye for the staining of receptors. The somatostatin receptor (sstr) was selected as the target and FITC-octreotate as the detective agent. We performed a blot analysis to detect sstr in the transfer membrane. The sstr2 recombinant protein or cell lysate from a small cell lung carcinoma cell line (H69) was boiled and loaded onto SDS-PAGE, and the proteins were transferred to a membrane...
2017: PloS One
https://www.readbyqxmd.com/read/28178157/the-prognostic-influence-of-the-proliferative-discordance-in-metastatic-pancreatic-neuroendocrine-carcinoma-revealed-by-peptide-receptor-radionuclide-therapy-case-report-and-review-of-literature
#17
Nathanaëlle Montanier, Juliette Joubert-Zakeyh, Caroline Pétorin, Pierre François Montoriol, Salwan Maqdasy, Antony Kelly
RATIONALE: Pancreatic neuroendocrine tumors (pNET) are rare slowly growing tumors with a high metastatic potential. Peptide receptor radionuclide therapy (PRRT) with radiolabeled analogues has been developed as a new tool for the management of metastatic well-differentiated (grade 1 and 2) neuroendocrine tumors expressing somatostatin receptor (SSTR2). Chemotherapy is the mainstay in the management of grade 3 (G3) unresectable pancreatic neuroendocrine carcinoma (pNEC). To date, no study has evaluated the efficacy of PRRT in such tumors...
February 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28176908/primary-neuroendocrine-breast-carcinomas-a-retrospective-analysis-and-review-of-literature
#18
Xin Yang, Youde Cao, Chen Chen, Lin Liu, Cheng Wang, Shengchun Liu
BACKGROUND: Primary neuroendocrine breast carcinomas (NEBCs) are a rare type of breast carcinomas that lack comprehensive recognition, including the clinicopathological features, therapeutic strategies, and prognostic significance. The aim of this retrospective analysis is to present and analyze our own data of primary NEBCs. MATERIALS AND METHODS: We retrospectively reviewed the medical records from 2005 to 2015 in The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China to obtain a cohort of breast carcinoma patients who were confirmed to have primary NEBC by histopathology...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28176137/smarca4-deficient-sinonasal-carcinoma
#19
Abbas Agaimy, Wilko Weichert
The term "sinonasal undifferentiated carcinoma (SNUC)" has been coined in 1986 for a highly aggressive sinonasal tract epithelial neoplasm showing distinctive morphology, but lacking any specific line of differentiation. Recent developments resulted in a dynamic splitting of new entities traditionally included in the spectrum of SNUC. Sinonasal NUT-midline carcinoma, adamantinoma-like Ewing family tumors and most recently, SMARCB1(INI1)-deficient sinonasal carcinoma are the main entities defined by specific genetic aberrations...
February 7, 2017: Head and Neck Pathology
https://www.readbyqxmd.com/read/28174665/metastatic-small-cell-neuroendocrine-carcinoma-of-the-cervix-treated-with-the-pd-1-inhibitor-nivolumab-a-case-report
#20
Sarah E Paraghamian, Teresa C Longoria, Ramez N Eskander
BACKGROUND: Nivolumab is an immune checkpoint inhibitor specific for the programmed death 1 (PD-1) receptor that has led to clinical responses in many cancer types. Identifying biomarkers predictive of response to PD-1 blockade is an area of active investigation. CASE PRESENTATION: We present a patient with recurrent, metastatic, PD-L1-negative small cell neuroendocrine carcinoma of the cervix (SCNEC) who experienced a complete response to nivolumab. Though nivolumab was discontinued over 4 months ago due to treatment-related adverse events, she continues to have no evidence of disease...
2017: Gynecologic Oncology Research and Practice
keyword
keyword
39230
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"